News
Edgewise Therapeutics faces challenges with DMD/BMD programs, upcoming trial data concerns, and competitive risks.
Hosted on MSN8mon
Why Edgewise Therapeutics Stock Is Up 50% on ThursdayShares of biopharma outfit Edgewise Therapeutics (NASDAQ: EWTX) soared more than 50% today, reaching a three-year high following an update on the clinical testing of its cardiac drug EDG-7500.
Hosted on MSN1mon
Is Edgewise Therapeutics Inc. (NASDAQ:EWTX) the Most Promising Small-Cap Stock According to Analysts?In this article, we are going to take a look at where Edgewise Therapeutics Inc. (NASDAQ:EWTX) stands against other promising small-cap stocks. Robert Teeter of Silvercrest Asset Management ...
April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from the Phase 2 ...
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the ...
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference ...
BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten ...
in the first half of 2025 – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results